STRATA Skin Sciences Faces Delisting Notice

TL;DR

STRATA Skin Sciences got an 8-K notice about failing to meet listing rules - possible delisting.

AI Summary

STRATA Skin Sciences, Inc. filed an 8-K on October 14, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC, is based in Horsham, PA.

Why It Matters

This filing indicates potential issues with STRATA Skin Sciences' compliance with stock exchange listing requirements, which could lead to the delisting of its shares.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and investor confidence.

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• October 13, 2025 (date) — Earliest event reported
• October 14, 2025 (date) — Date of report
• MELA SCIENCES, INC. (company) — Former company name
• ELECTRO OPTICAL SCIENCES INC (company) — Former company name
• 5 Walnut Grove Drive, Suite 140, Horsham, PA 19044 (address) — Company business and mail address

FAQ

Key Financial Figures

• $0,001 — nge on which registered Common Stock, $0,001 par value per share SSKN The Nasdaq
• $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"

Filing Documents

• ea0261071-8k_strata.htm (8-K) — 28KB
• 0001213900-25-098755.txt ( ) — 191KB
• sskn-20251013.xsd (EX-101.SCH) — 3KB
• sskn-20251013_lab.xml (EX-101.LAB) — 33KB
• sskn-20251013_pre.xml (EX-101.PRE) — 22KB
• ea0261071-8k_strata_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on August 22, 2025, Strata Skin Sciences, Inc. (the "Company") received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"). On September 19, 2025, the Company submitted a plan to Nasdaq to regain compliance with the Stockholders' Equity Requirement (the "Plan"). In response to the Company's Plan, on October 13, 2025, Nasdaq provided the Company notice that Nasdaq has accepted the Plan and granted the Company an extension until February 16, 2026, to regain compliance with the Stockholders' Equity Requirement. The Company is currently evaluating various courses of action discussed with Nasdaq to regain compliance. There can be no assurance that the Company will be able to regain compliance. If the Company does not regain compliance by February 16, 2026, or if the Company fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company's common stock will become subject to delisting. In such event, Nasdaq rules permit the Company to appeal any delist determination. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

Forward-Looking Statements

Forward-Looking Statements Certain statements contained in this Current Report on Form 8-K are not historical facts and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. This information includes, without limitation, statements concerning the Company's intention or ability to regain compliance with the applicable Nasdaq listing requirements, the Company's intention to appeal the Nasdaq staff's determination, the Company's expectation that a request for a Panel hearing will stay the suspension of the Company's securities pending the Panel's decision, the timing and nature of any hearing before the Panel, the outcome of the Panel's review of any Company appeal of the Nasdaq staff's determination, and any courses of action to regain compliance with the applicable Nasdaq listing requirements. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Any forward-looking performance or events to differ materially from those expressed or implied in such statements. These and other risks are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of its annual report on Form 10-K for the fiscal year ended December 31, 2024, and any risks that may be contained in any subsequent filings that the Company makes with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Dated: October 14, 2025 By: /s/ John Gillings John Gillings Chief Accounting Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR